| Dates | Principal Investigator(s) |
Grant No./ Donor |
Title | Goal |
|---|---|---|---|---|
| 7/20-6/25 | Ralph Mason, PhD | 1R01CA244579, NIH/NCI | Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer | To develop the application of a novel vascular disrupting agent (VDA) in combination with leading therapies to enhance treatment of renal cell carcinoma (RCC) and improve tumor control. |
| 8/15-7/21 |
Carlos Arteaga, MD Ralph Mason, PhD: Director of Small Animal Imaging Resource |
P30 CA142543, NIH/NCI | UT Southwestern Cancer Center Support Grant | To support the infrastructure for the promotion of interdisciplinary, translational cancer research through the efforts of senior leadership, five scientific research programs, six shared resources, protocol specific research, protocol review and monitoring, planning and evaluation activities, developmental funds, community outreach and engagement, education and training, and administration. |
|
3/20-2/23 |
Li Zhang, PhD/ Li Liu, PhD Co-investigator: Ralph Mason, PhD |
RP200021, CPRIT | Optimizing Therapeutic Strategies Against Lung Cancer Using Multi-Modality Imaging | To determine the degree to which CycT (cyclopamine tartrate) and HSP2 (heme-sequestering peptide 2) alleviate tumor hypoxia and normalize tumor vasculature |
|
09/2022 – 06/2025 |
PI Lippert (UTSW Mason) |
CHE-2155170 SOUTHERN METHODIST UNIVERSITY/NSF |
1,2-Dioxetanes for Quantitative Chemiluminescence Imaging | Undertake chemiluminescent imaging in mice to assess increasingly sophisticated and refined chemiluminescent imaging agents being developed at SMU. |
|
04/2022 – 03/2027 |
MPI(Mason, Nguyen, Yang) |
1R01HL158204-01A1 UNIVERSITY OF TEXAS AT ARLINGTON/NIH |
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease | Long-term goal is to develop novel degradable dual-modal imaging nanoparticles (DINPs) to precisely deliver therapeutic reagents that provide cell protection and facilitate the formation of blood vessels de novo at ischemic sites while allowing detection of the NP location and monitoring of their therapeutic effectiveness for PAD treatment. |
|
08/31/2021-08/30/2026 |
PI: Henning | CPRIT RP210099 | North Texas Multimodal Small Animal Imaging Core Facility | The main goal of this proposal is to build a world-class pre-clinical multimodal imaging core facility to support the ongoing and future cancer research of nearly 100 different PIs from several institutions across North Texas. Mason oversees optical imaging. |